<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5615">
  <stage>Registered</stage>
  <submitdate>11/04/2012</submitdate>
  <approvaldate>11/04/2012</approvaldate>
  <nctid>NCT01577888</nctid>
  <trial_identification>
    <studytitle>Safety and Feasibility Study of the Shockwave Lithoplasty System</studytitle>
    <scientifictitle>Safety and Feasibility Study of the Shockwave Lithoplasty System</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TD-0047</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Vascular Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Shockwave System Treatment

Experimental: Lithotripsy Treatment - Shockwave System Treatment -Lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic peripheral arteries.


Treatment: devices: Shockwave System Treatment
Shockwave System Treatment during vascular disease intervention.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety determined by 30day New-Onset Serious Adverse Events - New Onset Serious Adverse Events (SAE) include death, device-related surgery or repeat hospitalization, occlusion, or major unplanned amputation through 30 days following the procedure.</outcome>
      <timepoint>30 day</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Angiographic Success as measured by residual stenosis &lt;30% reference vessel.</outcome>
      <timepoint>Peri-Procedural</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age &gt;18

          -  Patient or patient's legal representative have been informed of the nature of the
             study, agrees to participate and has signed the approved consent form.

          -  Female subjects of childbearing potential have a negative pregnancy test less than 7
             days before the procedure.

          -  Patient is able and willing to comply with all assessments in the study.

          -  Peripheral arterial disease of Rutherford Category 2, 3, 4, and 5.

          -  Ability to tolerate an antiplatelet agent (i.e. aspirin, clopidigrel or prasagrel).

          -  Meets Angiographic Inclusion Criteria</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients with peripheral arterial disease of Rutherford Category 6.

          -  Severe or infected gangrene of the lower extremity.

          -  Planned major amputation.

          -  Previously implanted stent at the treatment site.

          -  Patient with an externally-connected intracardiac catheter or pacemaker.

          -  Patient with an implantable pacemaker or defibrillator.

          -  Patient has connective tissue disease (e.g., Marfan's syndrome).

          -  Patient has a hypercoagulable disorder.

          -  Patient has allergy to imaging contrast media for which they cannot be premedicated.

          -  Patient is in acute renal failure or chronic renal insufficiency or failure as
             measured by a serum creatinine of &gt;19.5 Âµmol/L.

          -  Patient has active systemic infection.

          -  Patient has less than a one year life expectancy.

          -  Patient is pregnant or nursing.

          -  Patient is participating in another research study involving an investigational agent
             that has not reached the primary endpoint.

          -  Patient has other medical, social or psychological problems that, in the opinion of
             the investigator, preclude them from receiving this treatment, and the procedures and
             evaluations pre- and post-treatment.

          -  Chronic total occlusion of target vessel.

          -  Chronic total occlusion of inflow vessel.

          -  Highly tortuous arteries (bends greater than 30 degrees over the arc length of the
             balloon)

          -  Patients requiring concurrent intervention below the most distal target lesion.

          -  Inflow disease: Stenosis of &gt;50% in vessel proximal to the target lesion which
             requires treatment with Drug Eluting Balloon (DEB) or atherectomy.

          -  Prior procedure in target leg within past 3 months.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>6</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Shockwave Medical, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To study the early safety and performance of the Shockwave Medical System in subjects to
      demonstrate that the device can safely and effectively deliver localized energy for the
      treatment of vascular disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01577888</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew Holden, MD</name>
      <address>Auckland City Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>